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Many human pathogens produce phenotypic variants as a means to circumvent the host immune system and enhance
survival and, as a potential consequence, exhibit increased virulence. For example, it has been known for almost 90 y
that clinical isolates of the human bacterial pathogen group A streptococci (GAS) have extensive phenotypic
heterogeneity linked to variation in virulence. However, the complete underlying molecular mechanism(s) have not
been defined. Expression microarray analysis of nine clinical isolates identified two fundamentally different
transcriptomes, designated pharyngeal transcriptome profile (PTP) and invasive transcriptome profile (ITP). PTP and
ITP GAS differed in approximately 10% of the transcriptome, including at least 23 proven or putative virulence factor
genes. ITP organisms were recovered from skin lesions of mice infected subcutaneously with PTP GAS and were
significantly more able to survive phagocytosis and killing by human polymorphonuclear leukocytes. Complete
genome resequencing of a mouse-derived ITP GAS revealed that the organism differed from its precursor by only a 7-
bp frameshift mutation in the gene (covS) encoding the sensor kinase component of a two-component signal
transduction system implicated in virulence. Genetic complementation, and sequence analysis of covR/S in 42 GAS
isolates confirmed the central role of covR/S in transcriptome, exoproteome, and virulence modulation. Genome-wide
analysis provides a heretofore unattained understanding of phenotypic variation and disease specificity in microbial
pathogens, resulting in new avenues for vaccine and therapeutics research.
Citation: Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM (2006) Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype
and disease specificity. PLoS Pathog 2(1): e5.
Introduction
Bacterial pathogens have long been recognized to undergo
phenotypic variation (reviewed in [1]). Historically, interest in
this phenomenon has been fueled by the observation that
phenotypic variants can differ in pathogenesis character-
istics, such as increased or decreased virulence, or adaptation
to a particular anatomic site. Extensive work has been
directed at elucidating the molecular genetic events that
contribute to phenotypic variation, with antigenic variation
being the best-studied category. With few exceptions, most
studies have focused on analysis of a distinct phenotype such
as adhesin production or lipooligosaccharide structural
modiﬁcation. Several molecular mechanisms have been
documented to contribute to phenotypic variation, the most
common being slipped-strand mispairing events that result in
phase-variable expression of the associated gene [1].
The group A streptococci (GAS) cause many distinct
human infections [2]. Disease manifestations range from mild
infections such as pharyngitis (‘‘strep throat’’) and impetigo,
to extensive tissue destruction in the case of necrotizing
fasciitis (the ‘‘ﬂesh-eating’’ syndrome). Postinfection sequelae
such as rheumatic fever and glomerulonephritis can also
occur. The mechanisms that enable GAS to cause diverse
diseases are unknown, although both bacterial and host-
speciﬁc components are thought to be involved [3].
Associated morphologic and virulence variation in GAS has
been known for almost 90 y [4,5]. Classic studies identiﬁed
GAS phenotypic variation during invasive and upper respi-
ratory tract infections [4,6]. More recently, correlations have
been reported between the source of GAS clinical isolates and
their ability to invade human epithelial cells or secrete high
concentrations of virulence factors such as streptococcal
pyrogenic exotoxin A, B, and C (SpeA, SpeB, and SpeC), or
streptolysin O (SLO) [7–9]. Such correlations have been
observed for multiple GAS serotypes, including clonal
contemporary serotype M1 GAS [10]. The idea that GAS
phenotypic heterogeneity contributes to distinct disease
manifestations is supported by the identiﬁcation of inherited
alterations in virulence factor production when GAS is
passaged in human blood ex vivo or through mice [5,11–14].
Virulence factor production by GAS is regulated by stand-
alone transcription factors and two-component signal trans-
Editor: Partho Ghosh, University of California San Diego, United States of America
Received October 19, 2005; Accepted December 20, 2005; Published January 27,
2006
DOI: 10.1371/journal.ppat.0020005
This is an open-access article distributed under the terms of the Creative Commons
Public Domain declaration which stipulates that, once placed in the public domain,
this work may be freely reproduced, distributed, transmitted, modified, built upon,
or otherwise used by anyone for any lawful purpose.
Abbreviations: cov, control of virulence; GAS, group A streptococci; ITP, invasive
transcriptome profile; PMN, polymorphonuclear leukocyte; PTP, pharyngeal tran-
scriptome profile; SLO, streptolysin O; Spd3, Streptococcus pyogenes DNase 3; Spe,
streptococcal pyrogenic exotoxin; SPN, Streptococcus pyogenes NAD-glycohydro-
lase; TCS, two-component signal transduction system; THY, Todd-Hewitt broth with
yeast extract
* To whom correspondence should be addressed. E-mail: jmmusser@tmh.tmc.edu
PLoS Pathogens | www.plospathogens.org January 2006 | Volume 2 | Issue 1 | e5 0041duction systems (TCSs) [15]. Thirteen TCSs have been
described in GAS, of which the CovRS system (also known as
CsrRS)isthebestcharacterized.CovRSisanegativeregulatory
TCSthatdirectlyorindirectly inﬂuencesexpression of10% to
15% of GAS genes, including several virulence factors [16–21].
Despite these advances, we have an imprecise understand-
ing of the contribution of phenotypic variation to host–
pathogen interactions in GAS, and the molecular mecha-
nism(s) controlling this heterogeneity. Recently, genome-wide
investigative strategies have been used successfully to provide
new information about GAS population genetics, evolution,
and pathogenesis [22]. Inasmuch as phenotypic variation in
GAS may be a key component of the pathogen life cycle, we
chose to investigate this phenomenon using genome-wide
analytic strategies, including transcriptome proﬁling and
genome resequencing. Here we report genome, transcrip-
tome, and partial secretome differences that distinguish GAS
isolated from invasive and pharyngeal infections and permit a
heretofore unattainable understanding of phenotypic varia-
tion in a microbial pathogen.
Results
Transcriptome-BasedGroupingofSerotypeM1GASStrains
The transcriptomes of nine contemporary (post-1987)
serotype M1 GAS strains grown to early exponential phase
in Todd-Hewitt broth with yeast extract (THY) were analyzed
with an Affymetrix expression microarray. These nine strains
included six from patients with pharyngitis and three from
invasive disease episodes and were selected from approx-
imately 2,000 genetically characterized serotype M1 strains
[10]. Two very distinct transcriptome clusters were identiﬁed
based on analysis of the microarray data (Figure 1A). The
three invasive isolates formed one cluster termed an invasive
transcriptome proﬁle (ITP), and the six pharyngitis isolates
formed a second cluster termed a pharyngeal transcriptome
proﬁle (PTP).
The data imply that GAS strains cultured from patients
with pharyngeal and invasive disease have distinct tran-
scriptomes, which are retained upon in vitro growth. Analysis
of differential gene expression between the two transcrip-
tome proﬁles identiﬁed 89 genes that were statistically
signiﬁcant (t-test followed by a false discovery rate correction,
Q , 0.05) and transcribed 2-fold or greater between the two
proﬁles (increasing to 176 genes at a 1.5-fold change). The
mean fold change in transcripts of 24 selected virulence
factors or virulence factor regulators between the three ITP
and six PTP strains are shown in Figure 1B. How the
transcriptional variation of these 24 virulence factors/
regulators relate in context to the global transcriptional
variation occurring between the three ITP and six PTP strains
i ss h o w ni nF i g u r eS 1( s e eS u p p o r t i n gI n f o r m a t i o n ) .
Differential transcription of virulence factors between ITP
Figure 1. Differential Gene Expression of ITP and PTP GAS
(A) Principal component analysis plot showing transcriptome differences
between invasive (red) and pharyngeal (blue) isolates. Principal compo-
nent analysis assesses the variance in a dataset in terms of principal
components. The two most significant principal components are
displayed on the x- and y-axes. Ellipses (calculated using 2X standard
deviation for each gene per group) have been superimposed to highlight
group differences between ITP and PTP strains. Numbered data points
refertotheMGASstrainnumberfromwhichtheRNAsamplewasisolated.
The percentages of the total variation that are accounted for by the 1st
and 2nd principal components are shown on the x- and y-axes labels.
(B) Log10-fold transcript differences between the three ITP and six PTP
isolates shown in (A) for select virulence genes and virulence gene
regulators. Genes that are expressed higher in ITP isolates are shown in
red; those expressed higher in PTP isolates are shown in blue. All genes
shown are statistically significant (t-test followed by a false discovery rate
correction, Q , 0.05).
DOI: 10.1371/journal.ppat.0020005.g001
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Synopsis
Phenotypic heterogeneity within an infecting population is a
strategy commonly used by bacterial pathogens to evade the host
immune system and enhance survival. Such phenotypic variation
has been observed for the human pathogen group A streptococci
(GAS), which can cause a wide range of diseases with differing
severity. However, the underlying mechanisms that control this
variation, and the survival- and virulence-associated effects of this
variation, have not been fully elucidated.
By assaying total gene expression the authors found that clinical
GAS isolates from invasive and pharyngeal diseases had distinct
gene expression patterns during growth in standard laboratory
media. These two gene expression patterns conferred distinct
virulence-associated attributes on the expressing GAS strain, as
assessed using bacteremia and soft-tissue infection models of
disease. Likewise, the ability to survive the bactericidal activity of
human neutrophils was significantly different between GAS strains
with the two distinct expression patterns. Transition from one gene
expression pattern to the other required the mutation of the two-
component signal transduction system CovRS (control of virulence
R/S). The authors conclude that the ability of GAS to remodel its
transcriptome plays a major contribution in its ability to colonize
distinct niches of the human body and cause disease.and PTP isolates raises the possibility that certain GAS
virulence factors have a disease-speciﬁc function.
ITP GAS Are Derived from PTP GAS during Invasive
Infections
Inasmuch as the ITP GAS were isolated from cases of
invasive disease, we hypothesized that ITP GAS may be
derived from PTP GAS during invasive infections. To test this
hypothesis, GAS were isolated from the spleens and skin
lesions of mice euthanized 5 d after subcutaneous injection
with strain MGAS2221 (a representative PTP strain) or strain
MGAS5005 (a representative ITP strain) (Figure S2). A total of
approximately 1,000 colonies obtained from infected mice
were inspected visually for colony morphology. Colony
morphology was used as an initial indicator of transcriptional
proﬁle because PTP GAS are nonmucoid, whereas ITP GAS
are mucoid. This difference in colony morphology correlates
with the increased expression of the capsule synthesis operon
(hasABC) by ITP isolates (Figure 1B). Regardless of the colony
morphology of the original infecting strain, all GAS isolated
from the spleens of infected animals were mucoid. These data
imply that our hypothesis that PTP GAS have the ability to
transition to ITP GAS during invasive infections was correct.
More important, although all GAS isolated from the skin
lesions of mice infected with the ITP strain also were mucoid,
colonies grown from the skin lesions of PTP-infected mice
were a mixture of nonmucoid parental and mucoid variant
strains at approximately 1:1 ratio (Figure S2).
Toprovideadditionalevidencethatthemucoidderivativesof
strain MGAS2221 had ITPs, we performed Western immuno-
blots assessing reactivity of SpeA, SpeB, SLO, Streptococcus
pyogenes NAD-glycohydrolase (SPN, also known as NADase),
Mac, and S. pyogenes DNase 3 (Spd3). Mucoid and nonmucoid
derivatives of strain MGAS2221 had distinct protein secretion
patterns characteristic of ITP and PTP strains, respectively
(Figure 2A). Assays of culture supernatant SPN enzymatic
activityfurthersupportedtheideathatITPGAScanbederived
from PTP GAS during invasive infections (Figure S3).
Expression microarray analysis was used to determine if
the mucoid and nonmucoid mouse-passaged derivatives of
strain MGAS2221 had transcriptomes characteristic of ITP
and PTP GAS, respectively. The transcriptomes of 18
derivatives of strain MGAS2221 and six derivatives of strain
MGAS5005 grown to early exponential phase were analyzed
(Figure 2B and 2C, Table S1). As expected the mucoid
derivatives of PTP strain MGAS2221 clustered with the ITP
strain MGAS5005, conﬁrming a PTP to ITP transition (Figure
2B). Transcriptome differences between strain MGAS2221
and ITP mouse-passaged derivatives correlated strongly with
Figure 2. Mouse Passage Results in Recovery of ITP Derivatives from
Infecting PTP GAS
(A) Western immunoblots of supernatant proteins obtained from
overnight cultures of ITP and PTP GAS isolates, before and after mouse
passage. The amount of immunoreactive SpeA, SpeB, SLO/SPN, Spd3,
and Mac was unaffected by mouse passage of the ITP strain MGAS5005,
whereas they were affected by all spleen and some lesion-isolated GAS
after mouse passage of the PTP GAS isolate MGAS2221. Strains with a
mucoid colony morphology are indicated with an asterisk (*), while
nonmucoid strains are indicated by a hash (#).
(B) Principal component analysis plot portraying PTP to ITP transition for
several mouse-passaged derivatives of strain MGAS2221. The 2221 NM
(green) and 2221 M (purple) data points are mouse-passaged derivatives
of strain MGAS2221 with distinct nonmucoid and mucoid colony
morphologies, respectively. The 5005 M (orange) data points are
mouse-passaged derivatives of strain MGAS5005 that retain the mucoid
colony morphology of the parental strain. Ellipses (calculated using 2X
standard deviation for each gene per group) have been superimposed to
highlight differences between ITP and PTP GAS. The percentages of the
total variation that are accounted for by the 1st and 2nd principal
components are shown on the x- and y-axes labels.
(C) Log10-fold differences in transcripts for select virulence genes and
virulence gene regulators between all the PTP and ITP strains shown in
(B). Genes expressed higher in ITP derivatives are shown in red; those
expressed higher in PTP derivatives are shown in blue. RNA was isolated
from bacteria grown to the exponential phase of growth in THY media.
All genes shown are statistically significant as assessed by a t-test
followed by a false discovery rate correction of Q , 0.05.
DOI: 10.1371/journal.ppat.0020005.g002
PLoS Pathogens | www.plospathogens.org January 2006 | Volume 2 | Issue 1 | e5 0043
Virulence Variation between GASthose observed for clinical PTP and ITP isolates (correlation
coefﬁcient R
2 ¼ 0.76; Figure S4), further conﬁrming the
ability of M1 GAS to transition from PTP to ITP during an
invasive infection.
Differential Virulence of ITP and PTP GAS in Two Mouse
Models of Invasive Disease
To determine whether ITP and PTP GAS differed in ability
to cause invasive disease, isolates were compared in mouse
models of bacteremia and soft-tissue infection. Four ITP and
four PTP GAS strains were randomly chosen for study. In the
bacteremia model each of these eight strains was used to
infect 20 CD-1 mice by intraperitoneal injection. ITP GAS
were signiﬁcantly more virulent than PTP GAS in this model
of infection (p , 0.0001, logrank test; Figure 3A).
Next, the virulence of these eight ITP and PTP strains was
compared in a mouse model of soft-tissue infection. Fifteen
immunocompetent hairless mice were infected with each
strain. The average lesion volumes over time were signiﬁ-
cantly greater for mice infected with the PTP organisms than
ITP GAS (Figure 3B). Thus, in contrast to the bacteremia
model data, the soft-tissue infection study identiﬁed PTP GAS
as being more virulent than ITP GAS, as assessed by lesion
volume. Consistent with the increased virulence of the PTP
organisms during soft-tissue infection, four PTP infected
animals reached near death, whereas no ITP infected mice
reached this end point. Thus, it appears that the two distinct
transcriptomes of GAS bestow differential virulence, with ITP
GAS having increased virulence in bacteremia, and PTP GAS
having increased virulence in soft-tissue infections.
Differential Resistance of ITP and PTP GAS Strains to
Polymorphonuclear Leukocyte-Mediated Killing
Several of the virulence factors more highly expressed by ITP
GAS compared to PTP organisms have been reported to have
detrimental effects on host cells such as polymorphonuclear
leukocytes (PMNs), key mediators of innate immunity. For
example, streptococcal inhibitor of complement or Sic has been
shown to inhibit PMN function [23]. Thus we hypothesized that
ITP and PTP strains would differ signiﬁcantly in ability to be
killed by human PMNs. We found that ITP isolates were
signiﬁcantlymoreabletoresistkillingbyhumanPMNs(Figure4).
Figure 4. ITP and PTP GAS Show Differential Resistance to PMN-
Mediated Killing
Killing of ITP GAS strains MGAS5005 and 26PL1 by human PMNs occurred
at significantly lower levels than the PTP GAS strains MGAS2221 and
21PS1 (p , 0.001, analysis of variance with Bonferroni’s posttest for
multiple comparisons). Results shown are the mean 6 standard error of
the mean of four experiments.
DOI: 10.1371/journal.ppat.0020005.g004
Figure 3. Differential Virulence of ITP and PTP GAS in Mouse Models of
Invasive Disease
(A) ITP GAS are significantly more virulent than PTP GAS in a mouse
model of bacteremia (p , 0.0001, logrank test). Female CD-1 mice were
injected intraperitoneally with 2.5 3 10
7 CFU of GAS and lethality was
monitored. Four ITP and four PTP strains were each used to infect 20
mice. Survival curves were generated by pooling data from mice infected
with GAS strains of the same transcriptome profile.
(B) PTP GAS produce significantly larger lesion volumes than ITP GAS in a
mouse soft-tissue infection model (p , 0.01, mixed-model repeated-
measures analysis). Female Crl:SKH1-hrBR mice were injected subcuta-
neously with 1 3 10
7 CFU of GAS and monitored for skin lesion
formation. Shown are the average lesion volumes (6 standard error of
the mean) of mice pooled together based on the transcriptome profile of
the infecting strain. Fifteen mice were infected per GAS strain, with four
ITP and four PTP strains being used.
DOI: 10.1371/journal.ppat.0020005.g003
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Event Underpinning the PTP to ITP Transition
To test the hypothesis that the PTP to ITP transition is
associated with speciﬁc chromosomal mutations, microarray-
based sequencing (Nimblegen Systems) was used to compare
the entire genome of one PTP and three ITP isolates. As
expected, the genome sequence of strain MGAS5005 (ITP)
was identical to strain 52SL3, a mouse-passaged derivative of
strain MGAS5005 that also has an ITP (Table 1). The PTP
strain MGAS2221 and its mouse-passaged ITP derivative
strain 26PL1 had 20 common genetic changes relative to the
genome of strain MGAS5005 (Table 1). More important,
relative to parental strain MGAS2221 (PTP), strain 26PL1
(ITP) had only one genetic change. The unique mutation
consisted of a 7-bp insertion in covS, the gene encoding the
histidine kinase component of the negative regulatory TCS
CovRS. This frameshift mutation results in production of a
202-amino acid truncated CovS (wild-type CovS is 500 amino
acids in length). Of note, the ITP isolate MGAS5005 also has a
variant covS allele that truncates CovS. Taken together, these
observations provide strong support to the idea that
mutation of covS was responsible for the PTP to ITP
transition occurring during invasive infections and the
accompanying differential virulence characteristics.
To further examine the association of covR/S mutations
with transcriptome proﬁle, we sequenced these two genes
from 42 M1 GAS isolates (15 clinical and 27 mouse-passaged
derivatives of strains MGAS5005 and MGAS2221). All PTP
isolates had wild-type covR/S genes. In striking contrast, all
ITP isolates had either a mutated covR or covS gene (Table S1).
Thus, there was perfect correlation between the allelic state
of covR/S and the transcriptome proﬁle.
Complementation of the Variant covS Allele Found in
Strain MGAS5005 Results in Transition from ITP to PTP
The results above suggested that mutation of covR or covS
was the molecular mechanism responsible for PTP to ITP
transition in GAS. To further study the relationship between
covR/S alleles and transcriptome proﬁle, the covS variant allele
in strain MGAS5005 was complemented with a functional
CovS encoded by a plasmid. Transformation of strain
MGAS5005 with plasmid pDC123 did not affect the secreted
protein pattern, as determined by Western immunoblots
assaying SpeA, SpeB, SLO/SPN, Mac, and Spd3 reactivity
(Figure 5). In contrast, introduction of pDC123 encoding
CovS into strain MGAS5005 converted the secretion pattern
to one that was identical to PTP GAS isolates. Moreover,
curing of this plasmid from the complemented strain of
Figure 5. The ITP of MGAS5005 Is Due to a Variant covS Allele
Strain MGAS5005 was transformed with a derivative of plasmid pDC123
encoding a functional covS allele (pCovComp), and the supernatants
from overnight cultures were analyzed by Western immunoblot for SpeA,
SpeB, SLO/SPN, Mac, and Spd3 reactivity. Strain MGAS5005 transformed
with vector pDC123 retained the pattern of protein secretion identified
for MGAS5005 alone. In contrast, strain MGAS5005 transformed with
pCovComp had an altered exoprotein secretion pattern, which was
identical to that observed for PTP GAS (e.g., strain MGAS2221). Curing
plasmid pCovComp from complemented MGAS5005 returned the
secretion pattern to an ITP form.
DOI: 10.1371/journal.ppat.0020005.g005
Table 1. Genomic Differences Differentiating MGAS5005 from
the Isolates MGAS2221, 26PL1, and 52SL3
Genome
Location
a
DNA
Change
Gene Change
b MGAS
2221
26PL1 52SL3
293,185 þ1b p covS Wild-type Y Y N
293,726 þ7b p covS Frameshift N Y N
338,178 A ! G DNA polIII Nonsynonymous Y Y N
768,318 C ! A M5005_Spy0763 Nonsynonymous Y Y N
782,223 A ! G5 9 to scl n / a YYN
791,410 T ! A Iron (III)-binding Nonsynonymous Y Y N
850,211 A ! T Xanthine
permease
Nonsynonymous Y Y N
957,852 T ! C M5005_Spy0967/8 59 of genes Y Y N
1,046,961 T ! C dltA Nonsynonymous Y Y N
1,219,754 T ! C Ribose repressor Nonsynonymous Y Y N
1,233,518 A ! G M5005_Spy1279 Nonsynonymous Y Y N
1,391,298 A ! C Phage tail Synonymous Y Y N
1,458,313 A ! G P-glycerate
mutase
Nonsynonymous Y Y N
1,467,369 T ! C Stress response Nonsynonymous Y Y N
1,488,155 A ! G Fe3
þ siderophore Synonymous Y Y N
1,624,686 A ! G Oxidoreductase Synonymous Y Y N
1,636,815 A ! G Pullulanase Synonymous Y Y N
1,726,511 D IS element Not present Y Y N
1,732,435 C ! T Urocanate
hydratase
Synonymous Y Y N
1,749,727 T ! C Peptidase Synonymous Y Y N
1,809,719 T ! C Serine
dehydratase
Synonymous Y Y N
59 of genes refers to SNP located upstream of genes.
aLocation in MGAS5005 genome.
bChange relative to MGAS5005 sequence.
n/a, not applicable.
DOI: 10.1371/journal.ppat.0020005.t001
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MGAS5005 exoprotein proﬁle (Figure 5). Full (strain
MGAS6184) or partial (strain MGAS294) complementation
was also observed following introduction of the CovS
encoding plasmid into two additional clinical ITP GAS
strains (unpublished data). These data provide strong
evidence that the transcriptome proﬁle of GAS is intimately
linked to the allelic state of covR/S.
Discussion
Passage of GAS in human blood ex vivo or through mice
has long been known to produce strain derivatives with
enhanced virulence. This strain variation also is observed
among GAS clinical isolates, thereby raising the possibility
that such variation is an important contributor to disease
outcome. We used expression microarray and genome
resequencing to characterize transcriptome differences in
GAS variants and identify the underlying molecular mecha-
nism. We discovered that a single 7-bp insertion mutation in
the gene encoding the sensor kinase component of a TCS was
solely responsible for the tremendous number of transcript
differences distinguishing a PTP isolate from its ITP
derivative.
ITP and PTP GAS strains have very distinct transcriptomes
and cause signiﬁcantly different disease manifestations
(Figures 1 and 3). The increased virulence of ITP GAS in
the bacteremia model was linked to up-regulation of many
factors that inhibit PMN function, including capsule, Sic,
Mac, streptococcal DNase D2, C5a peptidase, S. pyogenes cell-
envelope protease, and other exoproteins that assist patho-
gen survival (Figures 1B and 3A) [23–27]. Increased produc-
tion of these virulence factors by ITP GAS occurs
concurrently with decreased production of SpeB, a broad-
spectrum cysteine protease virulence factor (Figure 2A [28–
30]). SpeB degrades ﬁbronectin, vitronectin, preinterleukin-
1B, and other host molecules [29,31]. More important, SpeB
also cleaves and inactivates bacterial proteins that contribute
to host–pathogen interactions, including many cell-wall
anchored and secreted GAS virulence factors such as M
protein [32]. Hence, despite the modest (1.16-fold) increase in
emm transcription in ITP strains (Figure S1), the relative
amount of mature M protein may be signiﬁcantly greater for
ITP strains because of the SpeB-mediated degradation of M
protein by PTP GAS. Thus, decreased SpeB production may
play a key role in the increased lethality of ITP GAS by
preserving GAS virulence factors [30,32,33]. Indeed, an
inverse correlation between in vitro SpeB expression and
human disease severity has been observed for contemporary
M1 GAS [9]. However, the in vivo consequences of this in
vitro observation are unclear. Indeed, despite minimal in
vitro SpeB expression by the highly virulent ITP strain
MGAS5005, this strain produces extensive amounts of SpeB
when grown ex vivo in human saliva [34].
Mice infected subcutaneously with PTP GAS had signiﬁ-
cantly larger skin lesions than animals injected with ITP
strains (all of which were covS
 ), an unexpected ﬁnding given
a previous report of increased lesion formation by a covS
mutant strain (Figure 3B [21]). Differences between the
animal studies reported by Engleberg et al. [21] and our
own include their use of Cytodex beads, a different inoculum
concentration, and smaller group sizes (n ¼ 5 mice). It is
possible that the 2-fold increase in transcription of the sag
operon (encoding streptolysin S) by PTP isolates is one
contributory factor for the larger lesion volumes observed
following PTP GAS infection (Figures 1B and 3B). Strepto-
lysin S is known to cause epithelial cell cytotoxicity, impede
phagocytic clearance of GAS, and promote tissue necrosis
[35,36]. It should be noted, however, that no difference was
observed between four ITP and four PTP GAS strains
following determination of hemolytic zone size after plating
on blood agar plates (unpublished data).
Transcription of the genes encoding streptokinase (ska),
Mac (mac), and capsule production (the has operon) are
repressed by CovRS [16–18,25], providing an explanation for
the increased expression of these genes by ITP GAS strains.
While CovRS represses the has operon directly, it is not
known whether repression of ska and mac is direct or indirect.
Recently, CovR has been shown to directly bind and repress
expression from the sagA promoter in vitro [37]. This
observation differs from that observed in the present study
where mutation of covR or covS resulted in a decrease in sagA
transcription (Figure 1B and 2C). In addition to encoding
streptolysin S, a noncoding RNA with gene regulatory
properties is also transcribed from the sag locus (also referred
to as pel for pleiotropic effect locus) [38]. This regulatory RNA
positively regulates the expression of several GAS virulence
factor-encoding genes including sic, nga, emm, and ska. As sagA
transcription is increased in PTP GAS strains this would be
expected to lead to increased transcription of sic, nga, emm,
and ska. However, transcription of these genes is decreased in
comparison to ITP GAS (Figure 1B). We believe that this
observation highlights the hierarchy and extensive cross-
talking that occurs between GAS transcriptional regulators.
That is, we believe that despite a greater concentration of
sagA RNA in PTP GAS strains (sagA
þþ, covR/S
þ), the tran-
scription of sic, nga, and ska are repressed compared to ITP
GAS (sagA
þ, covR/S
 ) due to CovRS-mediated repression.
In comparison to the sagA data, production of the
transcription factor-encoding gene rgg correlates well with
differences in known Rgg-regulated genes. Rgg acts as both a
positive (e.g., speB, grab) and negative (e.g., slo, mac) regulator
of transcription [39]. As rgg transcription is 3.8-fold higher in
PTP GAS, the increase in speB and grab transcription and
decrease in slo and mac transcription by PTP GAS isolates may
at least be partially mediated through greater Rgg activity.
Genome resequencing found that only a single 7-bp
insertion mutation in covS differentiated PTP strain
MGAS2221 from its ITP derivative (strain 26PL1), an
unexpected ﬁnding given the extensive differences in tran-
scriptome, exoproteome, and mouse virulence between these
strains. Although mutations in covR/S have been reported to
arise during mouse passage resulting in enhanced virulence
[21], the extensive effect of a covS mutation on the tran-
scriptome and resulting phenotypes was not known until the
studies reported herein. While we do not believe it to be the
case, the possibility that the genome resequencing study failed
to identify all genomic differences between strains cannot be
discounted. Documented limitations of the resequencing
array approach are difﬁculties in identifying DNA insertions,
DNA inversions, and expanded/retracted simple sequence
repeats. However, our resequencing arrays identiﬁed the 1-
and 7-bp insertions in covS, and the deletion of an insertion
sequence, upon conﬁrmation of putative polymorphisms by
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microarrays used in this study were powerful tools to identify
genetic differences between GAS strains at a whole genome
level. Even if genomic alterations were missed in our study, the
strong correlation between GAS transcriptional proﬁle and
covR/S genotype, coupled with covR/S complementation data,
strongly supports the notion that mutation of covR/S is
sufﬁcient for transition from PTP to ITP.
We hypothesize that PTP GAS are preferentially suited for
survival in the human pharynx. Consistent with this hypoth-
esis are recent reports that SpeB is required for growth and
persistence in saliva and protection from killing by LL-37, an
antimicrobial compound present in high levels in human
airway-surface ﬂuid [34,40]. Nyberg et al. [40] have reported
that binding of SpeB to the GAS cell surface protects the
pathogen from killing by LL-37 by targeted degradation of
this antibacterial factor. In this regard, we note that the gene
encoding GRAB, a GAS cell-surface protein that tethers a-2-
macroglobulin to the bacterial cell surface, is itself up-
regulated approximately 8-fold in PTP isolates (Figure 1B
[41]). The a-2-macroglobulin is a protease inhibitor that binds
and retains SpeB at the bacterial cell surface, protecting
against LL-37-mediated killing [40,41]. Thus, coordinated up-
regulation of SpeB and GRAB likely enhance survival of GAS
in the upper respiratory tract.
ITP GAS arise from PTP precursors during invasive
infections (Figures 2 and S2), presumably due in part to their
increased ability to escape PMN-mediated killing (Figure 4).
Since several of the antiphagocytic effectors made by ITP
strains are freely diffusible, PTP GAS present at the infection
site with ITP organisms might proﬁt from a ‘‘bystander’’
effect. Together, these processes increase the likelihood that
the infecting bacteria are able to disseminate to a new host.
We have not obtained evidence that ITP GAS can convert
to a PTP form. Similarly, we did not recover PTP GAS from
the upper respiratory tract of nonhuman primates with
experimental GAS pharyngitis induced by an ITP strain [26]
(unpublished data). These observations, coupled with the fact
that many distinct covR/S mutations were found in different
ITP isolates, lead us to conclude that the PTP to ITP
conversion is largely unidirectional. However, we cannot rule
out the possibility that transition of ITP to PTP GAS occurs at
a very low frequency due to back or second-site mutations.
Following the assumption that infecting GAS is a homoge-
neous population, clinical diagnostic laboratories generally
retain only one or a small number of colonies from each
infected patient. However, the data presented herein found
that both ITP and PTP GAS can be recovered from an
invasive infection (Figure S2). Thus, this observation may help
to explain the imperfect correlations between GAS pheno-
typic variation and disease source seen in this and other
studies (Table S1). Isolation of PTP GAS from an invasive
infection does not preclude ITP GAS from also playing an
important role.
Concluding Comment
Our genome-wide analysis has provided a precise explan-
ation for global modulation of phenotype and disease
speciﬁcity in a bacterial pathogen. A key discovery was the
extensive differential expression of known and putative
virulence factors between invasive and pharyngeal GAS
isolates. This ﬁnding provides new avenues for pathogenesis
studies and vaccine and therapeutics research. Inasmuch as
virtually all microbes undergo phenotypic variation, it is
reasonable to speculate that the genome-wide strategies used
herein will be fruitful in the study of other pathogens.
Materials and Methods
Bacterial strains. The serotype M1 GAS isolates studied are listed
in Table S1. All MGAS (Musser group A Streptococcus) strains were
isolated from clinical sources, whereas non-MGAS strains were
derived from either strain MGAS5005 (isolate names starting with
‘‘5’’) or MGAS2221 (isolate names starting with ‘‘2’’) inoculated
subcutaneously in mice (see below). The whole genome sequence of
strain MGAS5005 has recently been determined (see Accession
Numbers) [10]. The clinical isolates examined include organisms
obtained in comprehensive population-based studies conducted over
many years in the United States, Canada, and Finland [10]. The strains
studied were not subject to systematic sampling bias, and they
provide a temporally and spatially diverse collection of isolates.
Expression microarray analysis. A recently described custom-made
Affymetrix chip (Affymetrix, Santa Clara, California, United States)
was used for expression microarray studies [10,19]. The chip
consisted of an antisense oligonucleotide array (18 lm in size)
representing greater than 400,000 25-mer probes (16 pairs per probe
set). It contained probe sets (42,351 features) for 2,662 predicted GAS
ORFs representing a composite superset of six GAS genome
sequences (M1, M3, M5, M12, M18, and M49). The chip also contained
1,925 redundant probe sets that together represent greater than 95%
of the nonredundant predicted coding regions in the genome of
strain SF370.
GAS strains were grown overnight at 37 8C (5% CO2) in THY
broth. For the study comparing clinical isolates of GAS (Figure 1),
duplicate cultures of each strain were made by diluting (1:100)
overnight cultures into fresh prewarmed THY broth. For the study
comparing mouse-passaged derivatives of strains MGAS5005 and
MGAS2221 (Figure 2), single cultures were seeded from overnight
cultures, with the exception of strains MGAS5005 and MGAS2221 for
which triplicate cultures were seeded. Bacteria were grown at 37 8C
(5% CO2), and RNA was obtained in early exponential phase (OD600¼
0.14). RNA isolation, cDNA synthesis, labeling, and hybridization
were performed as described recently [10,19]. Gene expression
estimates were calculated using GCOS software v1.1.1 (Affymetrix).
Data were normalized across samples to minimize discrepancies that
can arise due to experimental variables (e.g., probe preparation,
hybridization). A two-sample t-test (unequal variance) was applied to
the data using the statistical package Partek Pro v5.1 (Partek, St.
Louis, Missouri, United States), followed by a false discovery rate
correction (Q , 0.05) to account for multiple testing.
Isolation of mouse-passaged GAS. Three groups of eight female
Crl:SKH10hrBR mice were injected subcutaneously with 100 llo f13
10
7 CFU of strain MGAS5005 in PBS, 1 3 10
7 CFU of strain
MGAS2221 in PBS, or sterile PBS. The mice were euthanized 5 d after
injection. The spleens and skin lesions were harvested, macerated in
500 ll PBS, and cultured overnight on blood agar plates. Single
colonies were picked, grown in 1 ml of THY broth for 7 h, and frozen
in liquid nitrogen after the addition of glycerol (ﬁnal concentration,
18%).
Western immunoblot analysis of culture supernatant proteins. GAS
were grown in THY broth (10 ml) to stationary phase (overnight), and
culture supernatants were obtained by centrifugation and ﬁltration
through a 0.22-lm ﬁlter. Proteins were precipitated by the addition
of 3.5 volumes ice-cold ethanol, collected by centrifugation, and
suspended in 500 ll of water. The anti-SLO antibody is known to
cross-react with both SLO and SPN because of the physical
association of these proteins in the immunizing antigen preparation
[10].
NADase enzyme activity assay. Secreted NADase activity was
assayed as described previously [10]. Brieﬂy, supernatants from
overnight cultures were centrifuged, ﬁltered, and 2-fold serial
dilutions were made in PBS. NAD
þ (Sigma, St. Louis, Missouri,
United States), diluted in PBS, was added to a concentration of 0.67
mM, and the reaction mixture was incubated for 1 h at 37 8C. NaOH
was added to 2 N, incubated for 1 h in the dark, and read by eye after
exciting the samples with 360-nm light. Results were reported as the
greatest 2-fold dilution of supernatant with no ﬂuorescence.
Mouse infection assays. Mice were infected with GAS grown to
midlogarithmic phase (OD600 approximately 0.55). ITP GAS strains
used in mice assays were MGAS294, MGAS5005, MGAS6184, and
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MGAS5456, MGAS9127, and 21PS1. For intraperitoneal injection, 20
female CD-1 mice were used for each GAS strain. The animals were
injected with 250 llo fa13 10
8 CFU/ml suspension of GAS in PBS.
Kaplan-Meier survival curves were generated and analyzed for
statistical signiﬁcance using the logrank test. For subcutaneous
inoculation, 15 female Crl:SKH10hrBR mice were injected with 100
llo fa13 10
8 CFU/ml suspension of GAS in PBS. Lesion areas and
volumes were determined daily for up to 2 wk as previously described
[26]. A mixed-model repeated-measures analysis was used to test for
signiﬁcant differences in lesion areas and volumes between GAS
strains. The repeated-measures model was employed with one within-
subjects and one between-subjects factor.
PMN-mediated killing assays. Killing of GAS by human PMNs was
determined as described previously [42], but with slight modiﬁcation.
In brief, PMNs (10
6) were combined with 10
7 unopsonized GAS in 96-
well plates on ice. Plates were centrifuged at 380 3 g for 5 min and
incubated at 37 8C for 60 min. PMNs were lysed with 0.1% saponin
(20 min on ice), and GAS were plated on THY or blood agar. Colonies
were counted and percentage GAS survival was calculated with the
equation
ðCFUPMNþ=CFUPMN Þ3100 ð1Þ
The assay measures total number of viable ingested and uningested
bacteria.
Microarray-based comparative genome resequencing. Genome
resequencing was performed by an array-based method (NimbleGen
Systems, Madison, Wisconsin, United States). The genome sequence
of serotype M1 strain MGAS5005 was used as the reference sequence
[10]. PCR and sequencing were used to verify all polymorphisms (see
Protocol S1).
Complementation of the covS mutation of strain MGAS5005. The
Escherichia coli–GAS shuttle vector pDC123 was used for complemen-
tation. The wild-type covR/S alleles from MGAS2221 were ampliﬁed
by PCR using primers COVRSF (59-gcttgcaagggttgtttgatg-39) and
COVRSR (59-gcggatccttaagctactctaactctc-39). Puriﬁed PCR product
was blunt ended, using the Klenow fragment of DNA PolI (New
England Biolabs, Beverly, Massachusetts, United States), and digested
with BamHI, which cuts within the site engineered into the COVRSR
primer (italicized). The PCR product was ligated into pDC123 after
digestion with BglII EcoRV, to create pCovComp, and the ligation
mixture was transformed directly into competent cells of strain
MGAS5005 by electroporation. The vector only also was transformed
into strain MGAS5005 to serve as a negative control. Transformation
mixtures were plated onto THY agar plates containing 4 lg/ml
chloramphenicol and incubated overnight at 37 8C (5% CO2). The
chromosomal and plasmid covR/S genes of transformants were
veriﬁed by PCR and sequencing.
Supporting Information
Figure S1. Global Transcriptome Variation between Clinical ITP and
PTP GAS Strains
The x-axis represents the whole genome sequence of contemporary
M1 GAS strain MGAS5005. The y-axis represents the mean relative
increase or decrease in gene transcription for the three clinical ITP
strains in relation to that observed for the six clinical PTP strains.
The dashed green lines represent 62-fold transcriptional difference.
Virulence factors/regulators transcribed .2-fold by ITP strains are
colored red. Virulence factors/regulators transcribed .2-fold by PTP
strains are colored blue. The emm gene, encoding the important
virulence factor M protein, is highlighted yellow for reference.
Found at DOI: 10.1371/journal.ppat.0020005.sg001 (155 KB PPT).
Figure S2. Schematic of Experiment Leading to Isolation of Mouse-
Passaged GAS Derivatives
PTP GAS (blue box, nonmucoid) or ITP GAS (red box, mucoid) were
injected subcutaneously into mice. Five days after infection mice
were euthanized and GAS isolated from spleens and skin lesions. ITP
GAS were isolated from the spleens and skin lesions of all infected
mice. GAS recovered from skin lesions of mice infected with PTP
GAS had an approximately 1:1 ratio of ITP to PTP GAS.
Found at DOI: 10.1371/journal.ppat.0020005.sg002 (9.2 MB PPT).
Figure S3. ITP Strains Secrete Increased NADase Activity Compared
to PTP Strains
NADase titers are shown on the y-axis, with different GAS strains
shown on the x-axis. Color coding is as described for Figure 2B. The
experiment was performed in duplicate and results identical to those
shown were obtained on both occasions. NEG, negative controls.
Found at DOI: 10.1371/journal.ppat.0020005.sg003 (29 KB PPT).
Figure S4. Correlation of Microarray Data between ITP/PTP GAS
Isolated from Clinical Sources and following Mouse Passage
The fold change in transcript levels (ITP relative to PTP) of 24
virulence-related genes from the clinical GAS microarray (Figure 1)
and the mouse-passaged GAS microarray (Figure 2) were log-
transformed and plotted against each other to evaluate their
correlation.
Found at DOI: 10.1371/journal.ppat.0020005.sg004 (44 KB PPT).
Protocol S1. Comparative Genomic Resequencing
Found at DOI: 10.1371/journal.ppat.0020005.sd001 (27 KB DOC).
Table S1. Serotype M1 Group A Streptococcus Isolates Studied
Found at DOI: 10.1371/journal.ppat.0020005.st001 (95 KB DOC).
Accession Numbers
Expression microarray data have been deposited at the Gene
Expression Omnibus database at National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/geo) and are accessible
through accession numbers GSE3899 and GSE3900.
The GenBank (http://www.ncbi.nlm.nih.gov) accession number for
the whole genome sequence of strain MGAS5005 is CP000017.
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